https://www.pharmaradar360.com/article/gene-therapy-for-inherited-blindness-set-for-mena-launch-under-ocugen-roots-pact-19b2fea93c5fdc14Pharma Surgeen2026-07-13T11:02:00.000ZGene therapy for inherited blindness set for MENA launch under Ocugen–Roots pacthttps://www.pharmaradar360.com/article/rare-disease-families-can-now-invest-in-biotech-gene-therapy-db90b2f26e641ab4Pharma Surgeen2026-07-13T11:00:00.000ZRare-Disease Families Can Now Invest In Biotech Gene Therapyhttps://www.pharmaradar360.com/article/ai-partnership-aims-to-sharpen-cancer-target-selection-at-veraxa-cba6b28832c04b43Pharma Surgeen2026-07-13T11:00:00.000ZAI partnership aims to sharpen cancer target selection at VERAXAhttps://www.pharmaradar360.com/article/fda-backs-pediatric-study-framework-for-armata-s-staph-infection-therapy-ap-sa02-456be7730829a005Pharma Surgeen2026-07-13T11:00:00.000ZFDA backs pediatric study framework for Armata’s Staph infection therapy AP-SA02https://www.pharmaradar360.com/article/2026-363bb9a36499ff1fPharma Surgeen2026-07-13T10:59:32.000ZΑνατιμολόγηση ΜΗΣΥΦΑ 2026 _ Προτεινόμενες τιμές προς διαβούλευσηhttps://www.pharmaradar360.com/article/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-31f29cb801f26da3Pharma Surgeen2026-07-13T10:59:00.000ZU.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/biotech-startup-funding-gap-widens-despite-rebound-in-vc-investment-76c75736cd856400Pharma Surgeen2026-07-13T10:52:43.000ZBiotech startup funding gap widens despite rebound in VC investmenthttps://www.pharmaradar360.com/article/jpmorgan-initiates-coverage-of-legend-biotech-legn-with-neutra-8e480a62464acae7Pharma Surgeen2026-07-13T10:50:16.000ZJPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutrahttps://www.pharmaradar360.com/article/the-wrong-way-to-compete-with-china-in-biotech-cf60d24e1b539f61Pharma Surgeen2026-07-13T10:35:46.000ZThe Wrong Way To Compete With China in Biotechhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-holder-to-resell-51-579-adss-under-rule-144-9d8fe7dbaec29010Pharma Surgeen2026-07-13T10:33:10.000ZTakeda Pharmaceutical (TAK) holder to resell 51,579 ADSs under Rule 144https://www.pharmaradar360.com/article/8-k-agenus-inc-reports-material-event-7a850300dc6093b2Pharma Surgeen2026-07-13T10:33:10.000Z[8-K] AGENUS INC Reports Material Eventhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-holder-to-sell-4-319-adss-from-rsu-awards-08e695cba9b4bffcPharma Surgeen2026-07-13T10:32:58.000ZTakeda Pharmaceutical (TAK) holder to sell 4,319 ADSs from RSU awardshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-nyse-tak-plans-sale-of-24-887-adss-valued-at-416-850-4e2502ae48df39fePharma Surgeen2026-07-13T10:32:57.000ZTakeda Pharmaceutical (NYSE: TAK) plans sale of 24,887 ADSs valued at $416,850https://www.pharmaradar360.com/article/china-s-pharmaceutical-innovation-30-of-global-drug-pipeline-and-record-deals-in-8b34ba0070daa384Pharma Surgeen2026-07-13T10:31:00.000ZChina’s Pharmaceutical Innovation: 30% of Global Drug Pipeline and Record Deals in 2026 - News and Statisticshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-files-notice-to-sell-7-889-adss-on-nyse-aa17accecc2f6ea0Pharma Surgeen2026-07-13T10:30:24.000ZTakeda Pharmaceutical (TAK) files notice to sell 7,889 ADSs on NYSEhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-holder-to-sell-54-210-adss-after-rsu-vesting-13085ac53373e464Pharma Surgeen2026-07-13T10:30:24.000ZTakeda Pharmaceutical (TAK) holder to sell 54,210 ADSs after RSU vestinghttps://www.pharmaradar360.com/article/tethis-expands-global-access-to-smartbiosurface-through-new-channel-partners-4174ac26287ef939Pharma Surgeen2026-07-13T10:28:38.000ZTethis expands global access to SmartBioSurface through new channel partnershttps://www.pharmaradar360.com/article/la-aemps-deja-de-emitir-la-comunicacion-de-la-decision-para-las-variaciones-ia-i-4a324b815286ffb5Pharma Surgeen2026-07-13T10:19:02.000ZLa AEMPS deja de emitir la comunicación de la decisión para las variaciones IA/IAin en procedimientos europeos en los que actúa como Estado Miembro Concernidohttps://www.pharmaradar360.com/article/pharmaceutical-direct-to-patient-distribution-models-outpace-existing-safety-ove-7062295955b47536Pharma Surgeen2026-07-13T10:17:32.000ZPharmaceutical Direct-to-Patient Distribution Models Outpace Existing Safety Oversight Infrastructurehttps://www.pharmaradar360.com/article/144-takeda-pharmaceutical-co-ltd-sec-filing-53ad25fdd21f90b2Pharma Surgeen2026-07-13T10:16:04.000Z[144] TAKEDA PHARMACEUTICAL CO LTD SEC Filinghttps://www.pharmaradar360.com/article/patient-safety-commissioner-annual-report-2025-to-2026-429f73f977e61214Pharma Surgeen2026-07-13T10:11:40.000ZPatient Safety Commissioner annual report 2025 to 2026https://www.pharmaradar360.com/article/cder-proposes-to-withdraw-approval-of-tavneos-a685cf2b34395291Pharma Surgeen2026-07-13T10:09:43.000ZCDER proposes to withdraw approval of TAVNEOShttps://www.pharmaradar360.com/article/goldman-sachs-initiates-erasca-stock-coverage-as-early-stage-biotech-84a525194ab45e74Pharma Surgeen2026-07-13T10:06:07.000ZGoldman Sachs initiates Erasca stock coverage as early-stage biotechhttps://www.pharmaradar360.com/article/agenus-announces-oversubscribed-private-placement-of-up-to-340-million-to-advanc-407a74298b4b551ePharma Surgeen2026-07-13T10:00:00.000ZAgenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancerhttps://www.pharmaradar360.com/article/denmark-urged-to-rework-confidential-drug-pricing-pilot-9d966d7ddee2652dPharma Surgeen2026-07-13T09:56:21.000ZDenmark urged to rework confidential drug pricing pilothttps://www.pharmaradar360.com/article/regulatory-round-up-13-july-2026-b1d4e37f6a1f5f7ePharma Surgeen2026-07-13T09:56:21.000ZRegulatory round-up: 13 July 2026https://www.pharmaradar360.com/article/iqirvo-broadens-liver-disease-case-with-phase-iii-result-ef6390f92dd1ce2cPharma Surgeen2026-07-13T09:56:15.000ZIqirvo broadens liver disease case with Phase III resulthttps://www.pharmaradar360.com/article/immunoglobulin-when-to-use-2bc3407cfc7e587bPharma Surgeen2026-07-13T09:53:35.000ZImmunoglobulin: when to usehttps://www.pharmaradar360.com/article/cosmos-pharmaceutical-corporation-provides-dividend-guidance-for-the-fiscal-year-8bdfe5a25bb87ae4Pharma Surgeen2026-07-13T09:50:56.000ZCOSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2027https://www.pharmaradar360.com/article/cambridge-biotech-files-for-ipo-as-it-awaits-fda-decision-on-sleep-apnea-pill-e9e52c363462e419Pharma Surgeen2026-07-13T09:48:00.000ZCambridge biotech files for IPO as it awaits FDA decision on sleep apnea pillhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-position-increased-by-sequoia-financial-84f75e221ab3ce09Pharma Surgeen2026-07-13T09:40:49.000ZTeva Pharmaceutical Industries Ltd. $TEVA Position Increased by Sequoia Financial Advisors LLChttps://www.pharmaradar360.com/article/cosmos-pharmaceutical-corporation-provides-consolidated-earnings-guidance-for-th-51d97f47c0cb23c1Pharma Surgeen2026-07-13T09:36:23.000ZCOSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending May 31, 2027https://www.pharmaradar360.com/article/fedex-launches-dedicated-life-sciences-organisation-3a9b460d8062b4f5Pharma Surgeen2026-07-13T09:23:44.000ZFedEx launches dedicated life sciences organisationhttps://www.pharmaradar360.com/article/signifor-7ee7a150bce85a2ePharma Surgeen2026-07-13T09:09:10.000ZSigniforhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-launches-plasma-ecosystem-initiative-in-indonesia-38ff4cb8769f6c54Pharma Surgeen2026-07-13T09:03:23.000ZTakeda Pharmaceutical (TAK) Launches Plasma Ecosystem Initiative in Indonesiahttps://www.pharmaradar360.com/article/returns-matter-nutx-214-cort-145-gkos-97-were-these-biotech-stocks-in-your-portf-f71315ad4b43cb61Pharma Surgeen2026-07-13T08:57:00.000ZReturns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio?https://www.pharmaradar360.com/article/fda-proposal-to-modernize-drug-manufacturing-registration-2e60627b7fbaebb9Pharma Surgeen2026-07-13T08:48:45.000ZFDA proposal to modernize drug manufacturing registrationhttps://www.pharmaradar360.com/article/erie-clinical-trial-for-eye-medicine-gives-pittsburgh-area-man-hope-db95bd958028dfb1Pharma Surgeen2026-07-13T08:45:00.000ZErie clinical trial for eye medicine gives Pittsburgh-area man hopehttps://www.pharmaradar360.com/article/appeal-by-huaheng-biotech-group-against-eu-duties-on-chinese-valine-released-3539550498971431Pharma Surgeen2026-07-13T08:36:00.000ZAppeal by Huaheng biotech group against EU duties on Chinese valine releasedhttps://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-october-to-dece-aad24e37abeac595Pharma Surgeen2026-07-13T08:30:40.000ZDHSC: senior officials’ business expenses, hospitality and meetings, October to December 2025https://www.pharmaradar360.com/article/building-the-foundation-for-the-orchestrated-lab-of-the-future-1d7f8f04904cb0faPharma Surgeen2026-07-13T08:19:55.000ZBuilding the foundation for the orchestrated lab of the futurehttps://www.pharmaradar360.com/article/jpmorgan-resumes-legend-biotech-stock-coverage-with-neutral-rating-b2469850d4f2f49cPharma Surgeen2026-07-13T08:17:46.000ZJPMorgan resumes Legend Biotech stock coverage with neutral ratinghttps://www.pharmaradar360.com/article/cabinet-launches-plan-to-attract-foreign-workers-for-ai-biotech-9b6f81d337293545Pharma Surgeen2026-07-13T08:16:54.000ZCabinet launches plan to attract foreign workers for AI, biotechhttps://www.pharmaradar360.com/article/in8bio-publishes-positive-phase-1-gbm-data-0d5ac6621bfa4670Pharma Surgeen2026-07-13T08:04:49.000ZIN8bio Publishes Positive Phase 1 GBM Datahttps://www.pharmaradar360.com/article/leo-pharma-reports-positive-phase-2-tralokinumab-results-ae1c879a37b639aaPharma Surgeen2026-07-13T08:01:33.000ZLEO Pharma Reports Positive Phase 2 Tralokinumab Resultshttps://www.pharmaradar360.com/article/once-monthly-vwd-shot-from-incyte-slashes-bleeding-in-early-trial-bec62739f4c03769Pharma Surgeen2026-07-13T08:00:00.000ZOnce‑monthly VWD shot from Incyte slashes bleeding in early trialhttps://www.pharmaradar360.com/article/drugmaker-vertex-spends-10b-to-buy-biotech-firm-to-expand-rare-disease-offerings-935dac17098ec67aPharma Surgeen2026-07-13T08:00:00.000ZDrugmaker Vertex spends $10B to buy biotech firm to expand rare-disease offeringshttps://www.pharmaradar360.com/article/top-emerging-biotech-hubs-in-2026-937a81aaf901e194Pharma Surgeen2026-07-13T07:59:31.000ZTop emerging biotech hubs in 2026https://www.pharmaradar360.com/article/candriam-s-c-a-makes-new-investment-in-teva-pharmaceutical-industries-ltd-teva-1ba1050e89209392Pharma Surgeen2026-07-13T07:54:19.000ZCandriam S.C.A. Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/fda-fast-track-designation-for-arialys-anti-nmda-therapy-adc125ef0eff463bPharma Surgeen2026-07-13T07:48:44.000ZFDA Fast-Track Designation for Arialys' Anti-NMDA Therapyhttps://www.pharmaradar360.com/article/mbrx-q1-2026-earnings-wider-than-expected-loss-as-clinical-stage-biotech-continu-0f68b61f53b627e6Pharma Surgeen2026-07-13T07:41:15.000ZMBRX Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Continues Pipeline Developmenthttps://www.pharmaradar360.com/article/puretech-subsidiary-celea-begins-phase-3-ipf-study-comparing-deupirfenidone-with-0e9795825e580c96Pharma Surgeen2026-07-13T07:16:27.000ZPureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)https://www.pharmaradar360.com/article/dimerix-asx-dxb-shares-slip-is-the-market-underestimating-the-biotechnology-comp-3e289aaf1d86cad7Pharma Surgeen2026-07-13T07:13:00.000ZDimerix (ASX:DXB) Shares Slip: Is the Market Underestimating the Biotechnology Company's Clinical Pipeline?https://www.pharmaradar360.com/article/price-to-sales-forward-of-tibet-rhodiola-pharmaceutical-holding-co-class-a-sse-6-0f9fb859fd23ce23Pharma Surgeen2026-07-13T07:11:42.000ZPrice to sales forward of Tibet Rhodiola Pharmaceutical Holding Co. Class A – SSE:600211https://www.pharmaradar360.com/article/navigating-the-new-eu-pharmaceutical-legislation-key-implications-for-pediatric-907a3e9ad068852bPharma Surgeen2026-07-13T07:10:08.000ZNavigating The New EU Pharmaceutical Legislation Key Implications For Pediatric Drug Developmenthttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-kintor-pharmaceutical-ltd-otc-kntpf-0f48578711f14795Pharma Surgeen2026-07-13T07:06:10.000ZEnterprise value to EBITDA forward of KINTOR PHARMACEUTICAL LTD. – OTC:KNTPFhttps://www.pharmaradar360.com/article/guidebook-on-channel-partner-training-medical-devices-india-c350baf6b0786ffcPharma Surgeen2026-07-13T07:01:41.000ZGuidebook on Channel Partner Training – Medical Devices (India)https://www.pharmaradar360.com/article/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi-13a9516017afc942Pharma Surgeen2026-07-13T07:00:45.000ZJemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancerhttps://www.pharmaradar360.com/article/u-s-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-3fd76facf2c83cd4Pharma Surgeen2026-07-13T06:58:36.000ZU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityhttps://www.pharmaradar360.com/article/aribio-receives-remaining-50-mil-payment-from-fosun-for-oral-alzheimer-s-drug-95378eaf37fea4f1Pharma Surgeen2026-07-13T06:51:34.000ZAriBio receives remaining $50 mil. payment from Fosun for oral Alzheimer’s drughttps://www.pharmaradar360.com/article/maharashtra-fda-orders-recall-of-2-45-crore-worth-of-aciloc-medicines-over-confu-5222cef3f52e6c25Pharma Surgeen2026-07-13T06:30:02.000ZMaharashtra FDA Orders Recall of ₹2.45 Crore Worth of Aciloc Medicines Over Confusing Brand Nameshttps://www.pharmaradar360.com/article/table-cosmos-pharmaceutical-2025-26-parent-results-d81e119bf812444bPharma Surgeen2026-07-13T06:30:00.000ZTABLE-Cosmos Pharmaceutical -2025/26 parent resultshttps://www.pharmaradar360.com/article/cosmos-pharmaceutical-sales-and-profits-rose-on-store-growth-with-fy2027-guidanc-69f8e8282d4d71ffPharma Surgeen2026-07-13T06:30:00.000ZCOSMOS Pharmaceutical: Sales and profits rose on store growth, with FY2027 guidance for higher sales and dividendshttps://www.pharmaradar360.com/article/hlb-plunges-as-fda-rejects-liver-cancer-drug-company-pursues-rapid-reapproval-ch-3c5495818305dacePharma Surgeen2026-07-13T06:27:00.000ZHLB plunges as FDA rejects liver cancer drug; company pursues rapid reapproval - CHOSUNBIZhttps://www.pharmaradar360.com/article/fda-advisory-no-2026-0778-public-health-warning-against-the-purchase-and-use-of-c102d3ab80f15a7fPharma Surgeen2026-07-13T06:20:52.000ZFDA Advisory No.2026-0778 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “STUNMEDICAL Line Fill Sub-Q Cross Linked Hyaluronic Acid with Lidocaine 1.0 mL” - Food and Drug Administrationhttps://www.pharmaradar360.com/article/price-to-book-forward-of-trinity-biotech-plc-sponsored-adr-fwb-trb0-76312bd1313a95b4Pharma Surgeen2026-07-13T06:08:07.000ZPrice to book forward of Trinity Biotech plc Sponsored ADR – FWB:TRB0https://www.pharmaradar360.com/article/celea-doses-first-patient-in-phase-3-ipf-drug-trial-by-investing-com-d03ecf3ea4db729aPharma Surgeen2026-07-13T06:07:16.000ZCelea doses first patient in phase 3 IPF drug trial By Investing.comhttps://www.pharmaradar360.com/article/celea-therapeutics-doses-first-patient-in-global-phase-3-surpass-ipf-trial-evalu-5475e15bcbd5f51bPharma Surgeen2026-07-13T06:00:00.000ZCelea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)https://www.pharmaradar360.com/article/puretech-founded-entity-celea-therapeutics-doses-first-patient-in-global-phase-3-2a8328817d79f2dfPharma Surgeen2026-07-13T06:00:00.000ZPureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)https://www.pharmaradar360.com/article/third-crl-for-elevar-hengrui-s-liver-cancer-combo-regimen-over-manufacturing-iss-3b737e2893be2653Pharma Surgeen2026-07-13T05:34:56.000ZThird CRL For Elevar/Hengrui’s Liver Cancer Combo Regimen Over Manufacturing Issueshttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-issues-3-million-paraad-convertible-notes-at-usd-1-0-d8b6adc7bf311a50Pharma Surgeen2026-07-13T05:03:08.000ZParadigm Biopharmaceuticals Issues 3 Million PARAAD Convertible Notes at USD $1.00 Each on 13 July 2026https://www.pharmaradar360.com/article/krystal-biotech-stock-and-2-biotech-names-with-pipeline-catalysts-bb5d1753c3f6974dPharma Surgeen2026-07-13T05:02:39.000ZKrystal Biotech Stock And 2 Biotech Names With Pipeline Catalystshttps://www.pharmaradar360.com/article/fda-orders-recall-of-2-45-crore-worth-of-aciloc-plus-medicines-over-risk-of-medi-cbf415e9fe70b2e1Pharma Surgeen2026-07-13T03:50:02.000ZFDA Orders Recall of ₹2.45 Crore Worth of Aciloc Plus Medicines Over Risk of Medication Confusionhttps://www.pharmaradar360.com/article/paradigm-secures-fresh-funds-to-advance-phase-3-knee-osteoarthritis-trial-e94eac2b0764f251Pharma Surgeen2026-07-13T03:32:23.000ZParadigm Secures Fresh Funds to Advance Phase 3 Knee Osteoarthritis Trialhttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-issues-3-million-convertible-notes-at-usd-1-00-each-9e0a7c7b7ac4807cPharma Surgeen2026-07-13T03:28:09.000ZParadigm Biopharmaceuticals Issues 3 Million Convertible Notes at USD $1.00 Each, Advancing US$27M Phase 3 OA Trial Fundinghttps://www.pharmaradar360.com/article/astrazeneca-licenses-respiratory-drug-from-sino-biopharma-in-potential-1-9-billi-31a778675fa010edPharma Surgeen2026-07-13T03:22:16.000ZAstraZeneca licenses respiratory drug from Sino Biopharma in potential $1.9 billion dealhttps://www.pharmaradar360.com/article/yakkyokukata-press-release-regarding-international-activities-related-to-pharmac-dd2e305ac4516e25Pharma Surgeen2026-07-13T03:00:00.000Z[YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia postedhttps://www.pharmaradar360.com/article/shinsa-checklist-for-quality-related-documents-for-biotechnology-products-derive-e64cdc015432ccc3Pharma Surgeen2026-07-13T03:00:00.000Z[SHINSA]Checklist for Quality-Related Documents for Biotechnology Products Derived from Cell Lines of Human or Animal Origin at the Time of Initial Clinical Trial Notification（Early Consideration）posted.https://www.pharmaradar360.com/article/daewoong-s-nabota-tops-1tri-in-cumulative-sales-fuels-global-aesthetics-ambition-8225051eaa75f730Pharma Surgeen2026-07-13T02:52:16.000ZDaewoong's Nabota tops ₩1tri. in cumulative sales, fuels global aesthetics ambitionshttps://www.pharmaradar360.com/article/aribio-has-received-all-60-million-about-90-billion-won-in-advance-of-options-un-7b67f4d2d1762b22Pharma Surgeen2026-07-13T02:17:27.000ZAribio has received all $60 million (about 90 billion won) in advance of options under the global co..https://www.pharmaradar360.com/article/south-korea-approves-wainua-autoinjector-for-hereditary-amyloid-neuropathy-chosu-c174a6d12beb78b8Pharma Surgeen2026-07-13T00:15:00.000ZSouth Korea approves Wainua autoinjector for hereditary amyloid neuropathy - CHOSUNBIZhttps://www.pharmaradar360.com/article/aribio-receives-full-upfront-payment-from-fosun-pharma-for-alzheimer-s-drug-deal-9a9bf755a52ebf3ePharma Surgeen2026-07-13T00:06:00.000ZAriBio Receives Full Upfront Payment From Fosun Pharma for Alzheimer's Drug Dealhttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-847efe7344c225c2Pharma Surgeen2026-07-13T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/santen-and-kyorin-announce-joint-marketing-agreement-in-japan-for-allergic-conju-5295b94aa4c50871Pharma Surgeen2026-07-13T00:00:00.000ZSanten and KYORIN announce joint marketing agreement in Japan for allergic conjunctivitis treatment Alesion® Eyelid Cream 0.5%https://www.pharmaradar360.com/article/otsuka-foods-to-revise-prices-of-some-products-new-prices-to-take-effect-with-de-e8963840638a34d9Pharma Surgeen2026-07-13T00:00:00.000ZOtsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of September 1, 2026https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-df698cc367e3b6aePharma Surgeen2026-07-13T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-0f7c56e36893d9b9Pharma Surgeen2026-07-13T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-6541e7269bbdd8b7Pharma Surgeen2026-07-13T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-b80a75c1ed8cb69ePharma Surgeen2026-07-13T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-f1be1c162d2e3167Pharma Surgeen2026-07-13T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-3e71422cefc22fb6Pharma Surgeen2026-07-13T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-dc583a7e2aba0874Pharma Surgeen2026-07-13T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-7350eb2add4d1b69Pharma Surgeen2026-07-13T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-4840b7fe80a863a9Pharma Surgeen2026-07-13T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-ca264b834763e540Pharma Surgeen2026-07-13T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-111049014b567128Pharma Surgeen2026-07-13T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-1b09add30f399f9cPharma Surgeen2026-07-13T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-cb027674dd41a929Pharma Surgeen2026-07-13T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-d4b747af48636784Pharma Surgeen2026-07-13T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/drug-establishment-registration-and-drug-listing-requirements-for-establishments-e5bea87722573411Pharma Surgeen2026-07-13T00:00:00.000ZDrug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishmentshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-abb1b0ff5618e0d9Pharma Surgeen2026-07-13T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-c1c34b64c042fdb0Pharma Surgeen2026-07-13T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Maternal and Child Health Bureau Performance Measures for Discretionary Grant Information System, OMB No. 0915-0298-Revisionhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-e73a69133ad43bcbPharma Surgeen2026-07-13T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-f5e567b028afbb3cPharma Surgeen2026-07-13T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-ac4662fc93dde211Pharma Surgeen2026-07-13T00:00:00.000ZCenter For Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/national-human-genome-research-institute-notice-of-meeting-ea0684d5d0362783Pharma Surgeen2026-07-13T00:00:00.000ZNational Human Genome Research Institute; Notice of Meetinghttps://www.pharmaradar360.com/article/new-global-report-outlines-strategies-to-improve-hematologic-care-for-women-8d55736043b3f7bcPharma Surgeen2026-07-13T00:00:00.000ZNew Global Report Outlines Strategies to Improve Hematologic Care for Womenhttps://www.pharmaradar360.com/article/zopapogene-imadenovec-drba-for-recurrent-respiratory-papillomatosis-43dbfa2307425b27Pharma Surgeen2026-07-13T00:00:00.000ZZopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis.https://www.pharmaradar360.com/article/a-meta-analysis-of-randomized-controlled-trials-of-functional-magnetic-resonance-6d3aadd9214c4884Pharma Surgeen2026-07-13T00:00:00.000ZA Meta-analysis of Randomized Controlled Trials of Functional Magnetic Resonance Imaging Neurofeedback for Training of Attention and Related Cognitive Functionshttps://www.pharmaradar360.com/article/acute-myocardial-infarction-in-young-adults-a-systematic-review-of-epidemiology-d56ba8f68c1110c8Pharma Surgeen2026-07-13T00:00:00.000ZAcute Myocardial Infarction in Young Adults: A Systematic Review of Epidemiology, Risk Factors, Clinical Features, Management, and Outcomeshttps://www.pharmaradar360.com/article/effects-of-custom-made-3d-printed-insoles-on-foot-and-body-alignment-in-stroke-s-fdf8cad7b614ae1bPharma Surgeen2026-07-13T00:00:00.000ZEffects of custom-made 3D-printed insoles on foot and body alignment in stroke survivors: an exploratory pilot randomized controlled trialhttps://www.pharmaradar360.com/article/the-health-belief-model-the-healthy-eating-habits-among-11th-grade-high-school-s-fc5a135942328289Pharma Surgeen2026-07-13T00:00:00.000ZThe Health Belief Model: The Healthy Eating Habits Among 11th-grade High School Students in Health Sciences Clusterhttps://www.pharmaradar360.com/article/the-correlation-between-physical-activity-and-fasting-blood-glucose-levels-among-c874d4c2e3e01bb4Pharma Surgeen2026-07-13T00:00:00.000ZThe Correlation Between Physical Activity And Fasting Blood Glucose Levels Among Employees of Universitas Swadaya Gunung Jati: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/focus-on-rare-tracheal-pathologies-you-should-not-miss-91af6d79c22d56ebPharma Surgeen2026-07-13T00:00:00.000ZFocus on Rare Tracheal Pathologies You Should Not Misshttps://www.pharmaradar360.com/article/different-models-of-everyday-physical-activity-and-occurrence-of-falls-among-com-ef32484974fc5c3bPharma Surgeen2026-07-13T00:00:00.000ZDifferent Models of Everyday Physical Activity and Occurrence of Falls Among Community-Dwelling Older Adults and Middle-Aged Citizenshttps://www.pharmaradar360.com/article/cognitive-impairment-and-dysphagia-associated-with-postoperative-hydrocephalus-s-b50509d74a2c73a9Pharma Surgeen2026-07-13T00:00:00.000ZCognitive Impairment and Dysphagia Associated with Postoperative Hydrocephalus Secondary to Cerebrospinal Fluid Leakage After C1–2 Fusion: A Case Reporthttps://www.pharmaradar360.com/article/clinical-and-surgical-risk-factors-for-wound-healing-disorders-following-non-ins-04c98e384cc70ec1Pharma Surgeen2026-07-13T00:00:00.000ZClinical and Surgical Risk Factors for Wound Healing Disorders Following Non-Instrumented Lumbar Spine Surgery Using Penalized Regression Analysishttps://www.pharmaradar360.com/article/time-to-rethink-ics-dosing-in-pursuit-of-asthma-clinical-remission-high-dose-ics-2892f284aba76a45Pharma Surgeen2026-07-13T00:00:00.000ZTime to Rethink ICS Dosing in Pursuit of Asthma Clinical Remission: High-Dose ICS/LABA May Restore Short-Term Asthma Control When Medium Doses Failhttps://www.pharmaradar360.com/article/targeting-the-rsv-and-hmpv-l-protein-cryo-em-and-structure-based-approaches-to-a-593dad7ead198096Pharma Surgeen2026-07-13T00:00:00.000ZTargeting the RSV and hMPV L Protein: Cryo-EM and Structure-Based Approaches to Antiviral Drug Discoveryhttps://www.pharmaradar360.com/article/effects-of-statins-on-functional-capacity-and-cardiac-remodeling-in-patients-wit-267f53da5f7e6c22Pharma Surgeen2026-07-13T00:00:00.000ZEffects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trialhttps://www.pharmaradar360.com/article/prognosis-of-pediatric-hepatic-wilson-disease-with-atp7b-loss-of-function-varian-c838a20357937fdaPharma Surgeen2026-07-13T00:00:00.000ZPrognosis of pediatric hepatic Wilson disease with ATP7B loss of function variantshttps://www.pharmaradar360.com/article/clinical-performance-of-nitrous-oxide-inhalation-versus-intravenous-sedation-in-41db06b9b55fc7a2Pharma Surgeen2026-07-13T00:00:00.000ZClinical Performance of Nitrous Oxide Inhalation versus Intravenous Sedation in Outpatient Dental Surgery: Efficacy and Safety Outcomeshttps://www.pharmaradar360.com/article/clinical-efficacy-and-safety-of-3d-miniplate-fixation-for-parasymphyseal-and-ang-b3cfe502b3026cd7Pharma Surgeen2026-07-13T00:00:00.000ZClinical Efficacy and Safety of 3D Miniplate Fixation for Parasymphyseal and Angle Fractures of the Mandible: A Prospective Studyhttps://www.pharmaradar360.com/article/prevalence-and-clinical-characteristics-of-psychodermatoses-among-patients-visit-86ea703fbc4a304aPharma Surgeen2026-07-13T00:00:00.000ZPrevalence and Clinical Characteristics of Psychodermatoses among Patients Visiting Dermatology Outpatient Department in a Tertiary Level Hospital in Bangladeshhttps://www.pharmaradar360.com/article/a-review-on-resmetirom-an-oral-thyroid-hormone-receptor-agonist-for-the-treatmen-45e75c79a23a2723Pharma Surgeen2026-07-13T00:00:00.000ZA Review on Resmetirom: An Oral Thyroid Hormone Receptor-β Agonist for the Treatment of Metabolically dysfunction-Associated Steatohepatitis (MASH)https://www.pharmaradar360.com/article/hepatitis-b-virus-in-pakistan-serological-marker-prevalence-clinical-correlates-5b6f24e40a0ac22dPharma Surgeen2026-07-13T00:00:00.000ZHepatitis B virus in Pakistan: serological marker prevalence, clinical correlates, and genotype-informed interpretationhttps://www.pharmaradar360.com/article/self-reported-adverse-drug-reactions-to-dolutegravir-based-first-line-antiretrov-6aa8ff94b1783a59Pharma Surgeen2026-07-13T00:00:00.000ZSelf-reported adverse drug reactions to Dolutegravir-Based First-Line Antiretroviral Therapy and associated factors in Ethiopian patients: A Cross-sectional studyhttps://www.pharmaradar360.com/article/the-high-volume-opd-problem-why-indian-clinical-documentation-requires-a-purpose-5d39173f48c00979Pharma Surgeen2026-07-13T00:00:00.000ZThe High-Volume OPD Problem: Why Indian Clinical Documentation Requires a Purpose-Built Artificial Intelligence Modelhttps://www.pharmaradar360.com/article/drug-of-abuse-screening-in-the-era-of-poct-a-persistent-technological-gap-61ede9483a6427bdPharma Surgeen2026-07-13T00:00:00.000ZDrug-of-abuse screening in the era of POCT: a persistent technological gaphttps://www.pharmaradar360.com/article/la-constitucion-de-1824-y-la-extincion-de-la-fisicatura-mor-impactos-en-la-ensen-622247ab2f907850Pharma Surgeen2026-07-13T00:00:00.000ZLa Constitución de 1824 y la extinción de la Fisicatura-mor: impactos en la enseñanza de farmacia y en la fiscalización del mercado de medicamentoshttps://www.pharmaradar360.com/article/laparoscopic-repair-of-a-rare-morgagni-hernia-a-case-report-af3ce262350005b7Pharma Surgeen2026-07-13T00:00:00.000ZLaparoscopic repair of a rare Morgagni hernia: A case reporthttps://www.pharmaradar360.com/article/the-efficacy-safety-and-impact-of-various-clinical-pathological-characteristics-85bb3c71133540bfPharma Surgeen2026-07-13T00:00:00.000ZThe efficacy, safety, and impact of various clinical-pathological characteristics on the adjuvant immune checkpoint blockade in resected melanomahttps://www.pharmaradar360.com/article/designing-clinical-research-on-hyperbaric-oxygen-therapy-a-narrative-review-and-af6d27e61dd96918Pharma Surgeen2026-07-13T00:00:00.000ZDesigning clinical research on hyperbaric oxygen therapy: a narrative review and practical methodological guidehttps://www.pharmaradar360.com/article/baseline-peripheral-blood-immune-markers-associated-with-clinical-outcomes-in-pa-1ccd6d45b901acffPharma Surgeen2026-07-13T00:00:00.000ZBaseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecanhttps://www.pharmaradar360.com/article/the-impact-of-spiritual-care-on-gestational-diabetes-self-management-a-randomize-23c64d4fa5a5632dPharma Surgeen2026-07-13T00:00:00.000ZThe impact of spiritual care on gestational diabetes self-management: a randomized controlled trialhttps://www.pharmaradar360.com/article/effect-of-preoperative-isometric-hand-exercise-on-vascular-caliber-in-patients-w-972976891118d4b2Pharma Surgeen2026-07-13T00:00:00.000ZEffect of preoperative isometric hand exercise on vascular caliber in patients with advanced chronic kidney disease - a randomised controlled trialhttps://www.pharmaradar360.com/article/adaptive-gaussian-process-search-for-simulation-based-sample-size-estimation-in-f91338caa94fb0fdPharma Surgeen2026-07-13T00:00:00.000ZAdaptive Gaussian process search for simulation-based sample size estimation in clinical prediction models: validation of the pmsims R packagehttps://www.pharmaradar360.com/article/a-nomogram-for-predicting-buccal-bone-coverage-at-the-implant-shoulder-in-bone-a-1b4a15b161adca36Pharma Surgeen2026-07-13T00:00:00.000ZA Nomogram for Predicting Buccal Bone Coverage at the Implant Shoulder in Bone Augmentation Using the Full‐Thickness Envelope Flap Technique: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/vibrational-spectroscopy-of-clinical-biofluids-advances-in-ftir-and-raman-based-f8745025c8f91801Pharma Surgeen2026-07-13T00:00:00.000ZVibrational Spectroscopy of Clinical Biofluids: Advances in FTIR and Raman-Based Biomarker Discovery for Disease Diagnosis and Monitoringhttps://www.pharmaradar360.com/article/the-role-of-medium-intensity-training-in-promoting-functional-independence-and-c-f7a9918b9c73311dPharma Surgeen2026-07-13T00:00:00.000ZThe role of medium-intensity training in promoting functional independence and cognitive function in older adults: a randomized controlled trialhttps://www.pharmaradar360.com/article/drug-tolerant-persisters-to-trail-emerge-from-a-dose-dependent-surface-in-a-cell-7412d2036e31785dPharma Surgeen2026-07-13T00:00:00.000ZDrug-tolerant persisters to TRAIL emerge from a dose-dependent surface in a cell-state continuum of sensitivityhttps://www.pharmaradar360.com/article/glucagon-like-peptide-1-receptor-activation-and-mental-health-a-drug-target-mend-eab8b6b22a76fd8ePharma Surgeen2026-07-13T00:00:00.000ZGlucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization studyhttps://www.pharmaradar360.com/article/randomized-phase-2-trial-of-cpx-351-vs-clag-m-cladribine-cytarabine-g-csf-and-mi-c6bf32f4fb0a239ePharma Surgeen2026-07-13T00:00:00.000ZRandomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasmshttps://www.pharmaradar360.com/article/effects-of-a-low-glycemic-moderately-carbohydrate-restricted-diet-on-hepatic-lip-f2549ed1714ab5aePharma Surgeen2026-07-13T00:00:00.000ZEffects of a low-glycemic, moderately-carbohydrate restricted diet on hepatic lipid content and insulin sensitivity in adolescents with MASLD: protocol of a 6-month family-based, randomized controlled trialhttps://www.pharmaradar360.com/article/sexual-dysfunction-among-males-living-with-hiv-receiving-dolutegravir-based-anti-93806c851348fcf5Pharma Surgeen2026-07-13T00:00:00.000ZSexual Dysfunction Among Males Living with HIV Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross-sectional Studyhttps://www.pharmaradar360.com/article/phytocompounds-with-immunomodulatory-activities-mechanisms-therapeutic-potential-bd4321a2431bd944Pharma Surgeen2026-07-13T00:00:00.000ZPhytocompounds with immunomodulatory activities: mechanisms, therapeutic potential, and clinical prospectshttps://www.pharmaradar360.com/article/distinct-clinical-characteristics-and-prognostic-factors-of-pediatric-meningioma-90688938791487abPharma Surgeen2026-07-13T00:00:00.000ZDistinct clinical characteristics and prognostic factors of pediatric meningiomas in a 10-year cohort of 198 patientshttps://www.pharmaradar360.com/article/flow-diversion-in-proximal-superior-cerebellar-artery-aneurysms-systematic-revie-49ff0d6539473961Pharma Surgeen2026-07-13T00:00:00.000ZFlow diversion in proximal superior cerebellar artery aneurysms: Systematic review of clinical outcomes and exploratory hemodynamic analysishttps://www.pharmaradar360.com/article/hlb-determined-to-retry-liver-cancer-drug-approval-multiple-cases-of-fda-approva-61eaf1b3ad4dde74Pharma Surgeen2026-07-12T23:57:26.000ZHLB Determined to Retry Liver Cancer Drug Approval: "Multiple Cases of FDA Approval After Three CRLs"https://www.pharmaradar360.com/article/aribio-secures-90-billion-won-from-fuxing-as-ar1001-nears-phase-3-topline-chosun-06d96ae433fc87c0Pharma Surgeen2026-07-12T23:56:00.000ZAribio secures 90 billion won from Fuxing as AR1001 nears phase 3 topline - CHOSUNBIZhttps://www.pharmaradar360.com/article/u-s-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-b323af9cd44343baPharma Surgeen2026-07-12T23:30:00.000ZU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityhttps://www.pharmaradar360.com/article/public-alert-no-034-2026-niger-republic-imposes-import-ban-on-bulmex-parboiled-r-640ba2d16600898bPharma Surgeen2026-07-12T19:44:13.000ZPublic Alert No. 034/2026 – Niger Republic Imposes Import Ban on Bulmex Parboiled Rice from India due to Metallic Contaminationhttps://www.pharmaradar360.com/article/over-100-food-ingredients-entered-the-us-food-supply-without-fda-safety-reviews-a513bc6d10b07799Pharma Surgeen2026-07-12T19:43:23.000ZOver 100 food ingredients entered the US food supply without FDA safety reviews, report findshttps://www.pharmaradar360.com/article/astrazeneca-turns-to-china-for-molecule-that-might-top-new-merck-copd-drug-a51716b9902a55d2Pharma Surgeen2026-07-12T19:37:17.000ZAstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drughttps://www.pharmaradar360.com/article/ascelia-pharma-defends-orviglance-trial-after-fda-rejection-shares-plunge-79-in-fe941f737e31acedPharma Surgeen2026-07-12T17:35:00.000ZAscelia Pharma Defends Orviglance Trial After FDA Rejection, Shares Plunge 79% in 2026https://www.pharmaradar360.com/article/silence-therapeutics-pv-data-could-wake-the-stock-initiating-buy-nasdaq-sln-d5f9e3d267039972Pharma Surgeen2026-07-12T17:21:11.000ZSilence Therapeutics: PV Data Could Wake The Stock (Initiating Buy) (NASDAQ:SLN)https://www.pharmaradar360.com/article/fda-to-adjust-food-safety-measures-94050f429ff098fcPharma Surgeen2026-07-12T16:00:00.000ZFDA to adjust food safety measureshttps://www.pharmaradar360.com/article/mmj-the-voice-dea-didn-t-want-to-hear-from-during-marijuana-rescheduling-hearing-332ac3b3fe00432aPharma Surgeen2026-07-12T15:56:52.000ZMMJ The Voice DEA Didn't Want to Hear From During Marijuana Rescheduling Hearingshttps://www.pharmaradar360.com/article/leqembi-subcutaneous-autoinjector-clinical-data-supports-similar-efficacy-and-sa-b27c055b0052785aPharma Surgeen2026-07-12T15:30:11.000ZLEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026https://www.pharmaradar360.com/article/helus-pharma-rated-speculative-buy-ahead-of-key-phase-3-trial-results-in-2026-fo-aeb6e5a6cb03c3d4Pharma Surgeen2026-07-12T14:06:14.000ZHelus Pharma rated speculative Buy ahead of key Phase 3 trial results in 2026 for depression drug HLP003.https://www.pharmaradar360.com/article/pharmaceutical-marketplaces-how-online-platforms-are-changing-drug-purchasing-83e344e8d4cfccb7Pharma Surgeen2026-07-12T11:02:28.000ZPharmaceutical marketplaces: How online platforms are changing drug purchasinghttps://www.pharmaradar360.com/article/blood-brain-barrier-crossed-denali-s-fda-approval-unlocks-alzheimer-s-pipeline-23e98e5bcde8a841Pharma Surgeen2026-07-12T10:57:01.000ZBlood-Brain Barrier Crossed: Denali’s FDA Approval Unlocks Alzheimer’s Pipelinehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-sichuan-goldstone-asia-pharmaceutical-inc-7a4105ab94b234bcPharma Surgeen2026-07-12T10:29:59.000ZEnterprise value to EBITDA forward of Sichuan Goldstone Asia Pharmaceutical, Inc. Class A – SZSE:300434https://www.pharmaradar360.com/article/etfs-investing-in-anhui-huaren-health-pharmaceutical-co-ltd-class-a-stocks-2b4537dd3eef3a1cPharma Surgeen2026-07-12T09:59:06.000ZETFs Investing in Anhui Huaren Health Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/abivax-s-obefazimod-met-primary-endpoint-in-phase-iii-abtect-trial-71c3cfb3242993a8Pharma Surgeen2026-07-12T09:55:52.000ZAbivax’s obefazimod met primary endpoint in Phase III ABTECT trialhttps://www.pharmaradar360.com/article/read-news-and-stories-about-faculty-of-pharmaceutical-medicine-f1c9672640bece4aPharma Surgeen2026-07-12T09:53:15.000ZRead News and Stories about Faculty of Pharmaceutical Medicinehttps://www.pharmaradar360.com/article/this-biotech-stock-could-surge-93-after-a-breakthrough-in-cancer-treatment-0cc30259ac27bc52Pharma Surgeen2026-07-12T09:51:55.000ZThis biotech stock could surge 93% after a breakthrough in cancer treatmenthttps://www.pharmaradar360.com/article/why-maharashtra-fda-flagged-cadila-pharmaceuticals-for-branding-concerns-a8ec48d6d8942ee6Pharma Surgeen2026-07-12T09:48:59.000ZWhy Maharashtra FDA Flagged Cadila Pharmaceuticals for Branding Concernshttps://www.pharmaradar360.com/article/orion-stock-reflects-steady-pharma-strategy-as-helsinki-listed-drug-maker-leans-23664a8a64ddaae3Pharma Surgeen2026-07-12T09:39:41.000ZOrion stock reflects steady pharma strategy as Helsinki-listed drug maker leans on specialty medicinhttps://www.pharmaradar360.com/article/chinese-drug-manufacturer-with-ccp-ties-imported-unauthorized-glp-1-drug-ingredi-ecde6f162642a72dPharma Surgeen2026-07-12T09:00:00.000ZChinese drug manufacturer with CCP ties imported unauthorized GLP-1 drug ingredientshttps://www.pharmaradar360.com/article/flour-crisis-looms-permit-dispute-threatens-supply-in-rawalpindi-and-islamabad-781357e1fe52c7a7Pharma Surgeen2026-07-12T08:36:00.000ZFlour Crisis Looms: Permit Dispute Threatens Supply in Rawalpindi and Islamabadhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-trinity-biotech-plc-sponsored-adr-fwb-trb0-daa730ea9f0b2f2ePharma Surgeen2026-07-12T08:34:08.000ZPrice to earnings forward of Trinity Biotech plc Sponsored ADR – FWB:TRB0https://www.pharmaradar360.com/article/a-subsidiary-product-of-northeast-pharmaceutical-000597-sz-has-been-newly-includ-4de40458109b17bcPharma Surgeen2026-07-12T08:29:33.000ZA subsidiary product of Northeast Pharmaceutical (000597.SZ) has been newly included in the National Essential Medicines List (2026 Edition).https://www.pharmaradar360.com/article/chinese-biotech-mindrank-secures-52m-to-advance-ai-designed-oral-glp-1ra-e573f03c371ce830Pharma Surgeen2026-07-12T07:29:00.000ZChinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RAhttps://www.pharmaradar360.com/article/genmab-stock-reflects-the-biotech-group-s-global-oncology-ambitions-bb45e91c618f27eaPharma Surgeen2026-07-12T07:02:01.000ZGenmab stock reflects the biotech group's global oncology ambitionshttps://www.pharmaradar360.com/article/rs-2-45-crore-worth-of-aciloc-150-300-seized-in-maharashtra-fda-orders-recall-817a001962e8428fPharma Surgeen2026-07-12T07:02:00.000ZRs 2.45 crore worth of Aciloc 150+, 300+ seized in Maharashtra; FDA orders recallhttps://www.pharmaradar360.com/article/we-have-better-antihistamines-6e6b4cbc32badb6fPharma Surgeen2026-07-12T07:00:00.000ZWe have better antihistamineshttps://www.pharmaradar360.com/article/denecimig-shows-consistent-safety-and-efficacy-across-age-groups-in-hemophilia-a-18270a14d6c445c6Pharma Surgeen2026-07-12T06:53:57.000ZDenecimig shows consistent safety and efficacy across age groups in hemophilia A trialhttps://www.pharmaradar360.com/article/checkpoint-inhibitors-are-failing-recurrent-gbm-this-phase-1-trial-design-may-ex-d549d12d423f72e4Pharma Surgeen2026-07-12T06:48:57.000ZCheckpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial Design May Explain Why They Keep Trying.https://www.pharmaradar360.com/article/how-to-write-a-biotech-internship-email-in-2026-templates-examples-expert-tips-0886af1558fecfaePharma Surgeen2026-07-12T06:18:15.000ZHow to Write a Biotech Internship Email in 2026? Templates, Examples & Expert Tipshttps://www.pharmaradar360.com/article/maharashtra-fda-warns-against-three-cosmetics-after-mercury-lead-levels-exceed-s-d85f9dc4626795d6Pharma Surgeen2026-07-12T06:15:52.000ZMaharashtra FDA Warns Against Three Cosmetics After Mercury, Lead Levels Exceed Safety Limitshttps://www.pharmaradar360.com/article/fda-maharashtra-cracks-down-on-deceptive-drug-branding-ff534f22f6097385Pharma Surgeen2026-07-12T06:13:15.000ZFDA Maharashtra Cracks Down on Deceptive Drug Brandinghttps://www.pharmaradar360.com/article/new-research-suggests-high-blood-pressure-drug-telmisartan-enhances-efficacy-of-8a3649edce3cbc8cPharma Surgeen2026-07-12T06:05:03.000ZNew research suggests high blood pressure drug telmisartan enhances efficacy of PARP inhibitors in cancer treatmenthttps://www.pharmaradar360.com/article/maharashtra-fda-orders-recall-of-rs-2-45-crore-cadila-pharma-aciloc-stock-over-d-b44fe7a3540f889fPharma Surgeen2026-07-12T05:47:14.000ZMaharashtra FDA orders recall of Rs 2.45 crore Cadila Pharma Aciloc stock over deceptive brandinghttps://www.pharmaradar360.com/article/maharashtra-fda-seizes-cadila-pharma-s-rs-2-45-cr-worth-aciloc-stock-orders-mark-13f1ea00d6d9a0f8Pharma Surgeen2026-07-12T05:45:00.000ZMaharashtra FDA seizes Cadila Pharma's Rs 2.45 cr worth Aciloc stock; orders market recall over "deceptive" brandinghttps://www.pharmaradar360.com/article/medipost-begins-pivotal-u-s-phase-3-trial-for-regenerative-knee-therapy-cartiste-5d56f10145eecf16Pharma Surgeen2026-07-12T05:39:00.000ZMediPost Begins Pivotal U.S. Phase 3 Trial for Regenerative Knee Therapy Cartistemhttps://www.pharmaradar360.com/article/novartis-to-buy-uk-biotech-myricx-for-up-to-1-5-billion-boosting-adc-portfolio-ae9575eba2a11506Pharma Surgeen2026-07-12T05:37:00.000ZNovartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfoliohttps://www.pharmaradar360.com/article/us-fda-approves-first-wearable-injector-cancer-drug-de6871f4246d125aPharma Surgeen2026-07-12T04:56:43.000ZUS FDA Approves First Wearable Injector Cancer Drughttps://www.pharmaradar360.com/article/world-pipemidic-acid-market-analysis-forecast-size-trends-and-insights-fc2848f85036bea4Pharma Surgeen2026-07-12T03:56:12.000ZWorld Pipemidic Acid - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/hansoh-pharma-s-hs-20093-becomes-world-s-first-b7-h3-adc-to-show-positive-os-six-5a2ef5be804b7d9dPharma Surgeen2026-07-12T03:55:00.000ZHansoh Pharma's HS-20093 Becomes World's First B7-H3 ADC to Show Positive OS; Six Licensing Deals in Six Years Chart a Clearer Path Overseashttps://www.pharmaradar360.com/article/be-sure-to-check-out-windlas-biotech-limited-nse-windlas-before-it-goes-ex-divid-2b197a1e6c84752bPharma Surgeen2026-07-12T02:41:02.000ZBe Sure To Check Out Windlas Biotech Limited (NSE:WINDLAS) Before It Goes Ex-Dividendhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-coll-draws-fresh-valuation-attention-is-it-still-a-barg-e7aa460df77eaea6Pharma Surgeen2026-07-12T02:31:05.000ZCollegium Pharmaceutical (COLL) Draws Fresh Valuation Attention, Is It Still A Bargain?https://www.pharmaradar360.com/article/the-next-drug-lab-is-in-orbit-3466ddce88376223Pharma Surgeen2026-07-12T02:14:10.000ZThe next drug lab is in orbithttps://www.pharmaradar360.com/article/bay-area-biotech-giant-to-lay-off-103-employees-f9672130e758bd10Pharma Surgeen2026-07-12T02:05:56.000ZBay Area biotech giant to lay off 103 employeeshttps://www.pharmaradar360.com/article/daily-brief-health-care-pharmaron-ziyond-pharmaceutical-boston-scientific-and-mo-ee1df4e5fa89d936Pharma Surgeen2026-07-12T02:02:06.000ZDaily Brief Health Care: Pharmaron, Ziyond Pharmaceutical, Boston Scientific and morehttps://www.pharmaradar360.com/article/daily-brief-china-pharmaron-shein-weichai-lovol-intelligent-agricultural-technol-9613a1551c0b4c62Pharma Surgeen2026-07-12T02:01:05.000ZDaily Brief China: Pharmaron, SHEIN, Weichai Lovol Intelligent Agricultural Technology, Ziyond Pharmaceutical and morehttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875Pharma Surgeen2026-07-12T02:00:52.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/amgen-stock-steadies-as-the-biotech-group-leans-on-scale-59becc278ff8923cPharma Surgeen2026-07-12T02:00:11.000ZAmgen stock steadies as the biotech group leans on scalehttps://www.pharmaradar360.com/article/daily-brief-equity-bottom-up-china-biotech-sector-pharmaron-s-one-stop-shop-and-f1352df089d31c6bPharma Surgeen2026-07-12T02:00:04.000ZDaily Brief Equity Bottom-Up: CHINA BIOTECH SECTOR: Pharmaron's One Stop Shop! and morehttps://www.pharmaradar360.com/article/maharashtra-fda-raids-18-locations-suspends-licences-and-orders-recall-of-aciloc-8e9e0f9aa98c4a10Pharma Surgeen2026-07-12T01:59:00.000ZMaharashtra FDA raids 18 locations, suspends licences and orders recall of Aciloc medicineshttps://www.pharmaradar360.com/article/zevay-glp-1-review-2026-could-this-lower-cost-telehealth-option-be-the-right-fit-dbd42ad151f83885Pharma Surgeen2026-07-12T01:10:00.000ZZevay GLP-1 Review 2026: Could This Lower-Cost Telehealth Option Be the Right Fit for Your Weight-Management Goals?https://www.pharmaradar360.com/article/what-is-inhibrx-biosciences-inc-inbx-stock-business-overview-development-history-cb76eac714cef8fdPharma Surgeen2026-07-12T01:00:00.000ZWhat is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development historyhttps://www.pharmaradar360.com/article/certain-a-shares-of-jiangxi-tianxin-pharmaceutical-co-ltd-are-subject-to-a-lock-f012ea2073b1b99bPharma Surgeen2026-07-12T00:35:26.000ZCertain A Shares of JiangXi Tianxin Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 12-JUL-2026.https://www.pharmaradar360.com/article/novonesis-stock-reflects-a-steady-biotech-profile-amid-enzyme-and-microbe-focus-19e7e581390717fbPharma Surgeen2026-07-12T00:15:21.000ZNovonesis stock reflects a steady biotech profile amid enzyme and microbe focushttps://www.pharmaradar360.com/article/simvastatin-loaded-lipid-based-nanocarriers-for-breast-cancer-therapy-from-mecha-712f4ab78d712881Pharma Surgeen2026-07-12T00:00:00.000ZSIMVASTATIN-LOADED LIPID-BASED NANOCARRIERS FOR BREAST CANCER THERAPY: FROM MECHANISTIC RATIONALE TO FORMULATION STRATEGIEShttps://www.pharmaradar360.com/article/engineering-lipid-nanocarriers-for-targeted-delivery-of-resveratrol-in-hepatocel-fa5b383633ab509aPharma Surgeen2026-07-12T00:00:00.000ZENGINEERING LIPID NANOCARRIERS FOR TARGETED DELIVERY OF RESVERATROL IN HEPATOCELLULAR CARCINOMAhttps://www.pharmaradar360.com/article/orodispersible-tablets-a-comprehensive-review-of-formulation-strategies-technolo-a41573afc7b9fe94Pharma Surgeen2026-07-12T00:00:00.000ZORODISPERSIBLE TABLETS: A COMPREHENSIVE REVIEW OF FORMULATION STRATEGIES, TECHNOLOGIES AND RECENT ADVANCEShttps://www.pharmaradar360.com/article/formulation-and-evaluation-of-bilayer-tablet-of-acebrophylline-and-n-acetylcyste-10c6f6844a8c5e95Pharma Surgeen2026-07-12T00:00:00.000ZFORMULATION AND EVALUATION OF BILAYER TABLET OF ACEBROPHYLLINE AND N-ACETYLCYSTEINEhttps://www.pharmaradar360.com/article/nanocarrier-based-delivery-of-5-fluorouracil-in-breast-cancer-targeting-tumor-mi-a12d7cf5acdb3263Pharma Surgeen2026-07-12T00:00:00.000ZNANOCARRIER-BASED DELIVERY OF 5-FLUOROURACIL IN BREAST CANCER: TARGETING TUMOR MICROENVIRONMENT AND OVERCOMING CHEMORESISTANCEhttps://www.pharmaradar360.com/article/metabolic-associated-steatotic-liver-disease-and-cognitive-impairment-shared-pat-e99d63ee10ca458aPharma Surgeen2026-07-12T00:00:00.000ZMetabolic-Associated Steatotic Liver Disease and Cognitive Impairment: Shared Pathophysiological Mechanisms and Clinical Implications: A Narrative Reviewhttps://www.pharmaradar360.com/article/determinants-and-consequences-of-patient-and-health-system-delays-in-tuberculosi-b6c8cefff0fd6e2fPharma Surgeen2026-07-12T00:00:00.000ZDeterminants and Consequences of Patient and Health System Delays in Tuberculosis Diagnosis and Treatment Among Individuals Aged ≥15 Years at Kenyatta National Hospital, Nairobi, Kenyahttps://www.pharmaradar360.com/article/bmi-stratified-predictors-of-recurrence-after-inguinal-hernia-repair-the-role-of-618b453535590ed4Pharma Surgeen2026-07-12T00:00:00.000ZBMI-stratified predictors of recurrence after inguinal hernia repair: The role of perioperative celecoxib and dexamethasonehttps://www.pharmaradar360.com/article/neuropharmacological-assessment-of-intrathecal-thyrotropin-releasing-hormone-in-91ce9bc5972e45ebPharma Surgeen2026-07-12T00:00:00.000ZNeuropharmacological assessment of intrathecal thyrotropin-releasing hormone in cerebral ischemiahttps://www.pharmaradar360.com/article/pharmacological-strategies-for-slowing-the-rise-of-creatinine-and-urea-nitrogen-f90cb071dc5c2675Pharma Surgeen2026-07-12T00:00:00.000ZPharmacological strategies for slowing the rise of creatinine and urea nitrogen in diabetic kidney disease: A scoping reviewhttps://www.pharmaradar360.com/article/calme-a-cognitive-loop-for-in-action-ethical-deliberation-in-clinical-practice-3cf5ca98bf3a0da1Pharma Surgeen2026-07-12T00:00:00.000ZCALME: A Cognitive Loop for In-Action Ethical Deliberation in Clinical Practicehttps://www.pharmaradar360.com/article/kyphoplasty-a-comprehensive-review-of-procedural-techniques-patient-selection-an-350777aee9ac13f0Pharma Surgeen2026-07-12T00:00:00.000ZKyphoplasty: A Comprehensive Review of Procedural Techniques, Patient Selection, and Clinical Outcomes in the Treatment of Vertebral Compression Fractureshttps://www.pharmaradar360.com/article/comparative-effectiveness-of-a-nurse-led-care-model-vs-usual-care-in-rheumatoid-504d01e109639063Pharma Surgeen2026-07-12T00:00:00.000ZComparative Effectiveness of a Nurse-Led Care Model vs Usual Care in Rheumatoid Arthritis: A Longitudinal Cohort Study of Clinical Outcomes and Patient Adherencehttps://www.pharmaradar360.com/article/age-related-differences-in-clinical-outcomes-and-lung-function-trajectories-in-n-bd9701d65ac3796aPharma Surgeen2026-07-12T00:00:00.000ZAge-related differences in clinical outcomes and lung function trajectories in noncystic fibrosis bronchiectasis: a multicenter TBARC registry studyhttps://www.pharmaradar360.com/article/facilitating-access-to-clinical-data-from-a-randomized-controlled-trial-of-compl-5a0bd37b0096d4abPharma Surgeen2026-07-12T00:00:00.000ZFacilitating access to clinical data from a randomized controlled trial of complex adaptive designhttps://www.pharmaradar360.com/article/effect-of-fluralaner-administration-to-domestic-dogs-on-the-bloodmeal-profile-of-cee7a9842588189fPharma Surgeen2026-07-12T00:00:00.000ZEffect of fluralaner administration to domestic dogs on the bloodmeal profile of Triatoma infestans in a cluster-randomized trial in the Argentine Chacohttps://www.pharmaradar360.com/article/specimen-specific-distribution-of-multidrug-resistant-organisms-and-its-associat-6561404650959531Pharma Surgeen2026-07-12T00:00:00.000ZSpecimen-specific distribution of multidrug-resistant organisms and its association with glycemic control in adults with diabetes: a retrospective clinical microbiology study in southern Taiwanhttps://www.pharmaradar360.com/article/targeted-proteomics-for-the-detection-of-androgen-receptor-variants-in-preclinic-01b27bff4a1734d4Pharma Surgeen2026-07-12T00:00:00.000ZTargeted proteomics for the detection of androgen receptor variants in preclinical models of castration-resistant prostate cancerhttps://www.pharmaradar360.com/article/team-based-versus-individual-learning-for-out-of-hospital-cardiac-arrest-rhythm-185e055f33bce046Pharma Surgeen2026-07-12T00:00:00.000ZTeam-based versus individual learning for out-of-hospital cardiac arrest rhythm recognition in newly hired emergency medical service providers: cluster-randomized equivalence trialhttps://www.pharmaradar360.com/article/pyridine-based-derivatives-as-emerging-scaffolds-for-immunomodulatory-drug-devel-110a4f27c78d4547Pharma Surgeen2026-07-12T00:00:00.000ZPyridine-based derivatives as emerging scaffolds for immunomodulatory drug developmenthttps://www.pharmaradar360.com/article/masld-clinical-trials-increasing-enrollment-diversity-and-generalizability-752cb5829c107154Pharma Surgeen2026-07-12T00:00:00.000ZMASLD Clinical Trials: Increasing Enrollment, Diversity and Generalizabilityhttps://www.pharmaradar360.com/article/early-clinical-outcomes-of-keratoplasty-using-donor-corneas-preserved-in-sinasol-1c8128fc63fbb608Pharma Surgeen2026-07-12T00:00:00.000ZEarly clinical outcomes of keratoplasty using donor corneas preserved in sinasol (ZiSol) versus optisol-GShttps://www.pharmaradar360.com/article/ferroptosis-associated-immune-modulation-enhances-temozolomide-efficacy-in-exper-0803515b7c488fdbPharma Surgeen2026-07-12T00:00:00.000ZFerroptosis-associated immune modulation enhances temozolomide efficacy in experimental glioblastoma: potential implications for T-cell infiltration and tumour microenvironment dynamicshttps://www.pharmaradar360.com/article/rare-colorectal-manifestations-of-pediatric-gastrointestinal-lymphoma-a-systemat-339311c619d3e7f6Pharma Surgeen2026-07-12T00:00:00.000ZRare colorectal manifestations of pediatric gastrointestinal lymphoma: a systematic review of clinical spectrum and surgical implicationshttps://www.pharmaradar360.com/article/molecular-characterization-of-virulence-and-resistance-determinants-in-clinical-3e1fc44d649bdf39Pharma Surgeen2026-07-12T00:00:00.000ZMolecular characterization of virulence and resistance determinants in clinical Pseudomonas aeruginosa isolates: a cross-sectional analysis of virulence–resistance associationshttps://www.pharmaradar360.com/article/years-algorithm-for-diagnosis-of-suspected-pulmonary-embolism-in-patients-with-c-2396ead0770bec7cPharma Surgeen2026-07-12T00:00:00.000ZYEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancerhttps://www.pharmaradar360.com/article/what-s-driving-investor-interest-in-urogen-pharma-urgn-ahead-of-goldman-sachs-6939ffd6c7b46e0cPharma Surgeen2026-07-11T23:11:34.000ZWhat's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachshttps://www.pharmaradar360.com/article/nebraska-becomes-home-to-phase-3-trial-testing-novel-t-cell-engager-for-advanced-cc0b37642d5d5eaaPharma Surgeen2026-07-11T21:03:27.000ZNebraska Becomes Home to Phase 3 Trial Testing Novel T-Cell Engager for Advanced Prostate Cancerhttps://www.pharmaradar360.com/article/comp360-psilocybin-in-treatment-resistant-depression-insights-from-gus-alva-md-d-202069701b3000adPharma Surgeen2026-07-11T20:26:36.000ZCOMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPAhttps://www.pharmaradar360.com/article/healthcare-etfs-face-off-stability-vs-biotech-growth-which-strategy-wins-31f048fd98cfc268Pharma Surgeen2026-07-11T20:07:00.000ZHealthcare ETFs Face-Off: Stability vs. Biotech Growth, Which Strategy Wins?https://www.pharmaradar360.com/article/wst-stock-holds-steady-as-west-pharmaceutical-focuses-on-long-term-growth-11ac0bd21960b45fPharma Surgeen2026-07-11T20:02:20.000ZWST stock holds steady as West Pharmaceutical focuses on long-term growthhttps://www.pharmaradar360.com/article/fda-suspends-licence-of-salunkhe-vihar-road-cafe-over-hygiene-lapses-23cbb820748e5a77Pharma Surgeen2026-07-11T18:57:00.000ZFDA suspends licence of Salunkhe Vihar Road cafe over hygiene lapseshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hunan-warrant-pharmaceutical-co-ltd-class-a-4ef6a3e8184b4a03Pharma Surgeen2026-07-11T18:54:05.000ZEnterprise value to EBIT forward of Hunan Warrant Pharmaceutical Co., Ltd. Class A – SSE:688799https://www.pharmaradar360.com/article/which-is-best-for-investors-healthcare-stability-xlv-or-biotech-growth-ibbq-b4acd2fb40d9bef3Pharma Surgeen2026-07-11T18:45:00.000ZWhich is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?https://www.pharmaradar360.com/article/nvidia-invests-in-biotech-company-generate-biomedicines-e3126a5f7acff9dfPharma Surgeen2026-07-11T18:37:51.000ZNvidia Invests in Biotech Company Generate Biomedicineshttps://www.pharmaradar360.com/article/maharashtra-fda-bars-sale-of-cadila-pharmaceuticals-drugs-seizes-rs-2-45-crore-s-e3c4463970aac562Pharma Surgeen2026-07-11T18:19:08.000ZMaharashtra FDA bars sale of Cadila Pharmaceuticals drugs, seizes Rs 2.45 crore stockhttps://www.pharmaradar360.com/article/first-cannabis-based-medication-for-chronic-pain-to-launch-in-europe-07f30d3d2d1aa7c1Pharma Surgeen2026-07-11T18:10:16.000ZFirst Cannabis-Based Medication for Chronic Pain to Launch in Europehttps://www.pharmaradar360.com/article/which-is-best-for-investors-healthcare-stability-xlv-or-biotech-growth-ibbq-b6e7791782fb2b6aPharma Surgeen2026-07-11T18:05:00.000ZWhich is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?https://www.pharmaradar360.com/article/forget-glp-1s-glp-3s-show-promise-in-phase-3-weight-loss-and-diabetes-trial-431d801cba8a2e5dPharma Surgeen2026-07-11T17:20:01.000ZForget GLP-1s—GLP-3s show promise in phase 3 weight loss and diabetes trialhttps://www.pharmaradar360.com/article/nvidia-ceo-jensen-huang-said-ai-s-most-profound-impact-will-be-in-life-sciences-e17c1f426c92bceePharma Surgeen2026-07-11T16:37:00.000ZNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?https://www.pharmaradar360.com/article/maharashtra-fda-raid-tukaram-mundhe-orders-suspension-of-4-hotels-bakery-license-4ba191b9dcc2881fPharma Surgeen2026-07-11T16:25:56.000ZMaharashtra FDA Raid: Tukaram Mundhe Orders Suspension Of 4 Hotels, Bakery Licenses In Vasaihttps://www.pharmaradar360.com/article/pharmaceutical-society-of-ghana-medical-fraternity-mourn-distinguished-pharmacis-c1d13f9b41e59191Pharma Surgeen2026-07-11T16:17:53.000ZPharmaceutical Society of Ghana, medical fraternity mourn distinguished pharmacist Dr. Samuel Kwasi Nkansahhttps://www.pharmaradar360.com/article/nvidia-ceo-jensen-huang-said-ai-s-most-profound-impact-will-be-in-life-sciences-10865644bbeea8c8Pharma Surgeen2026-07-11T16:14:28.000ZNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?https://www.pharmaradar360.com/article/nvidia-ceo-jensen-huang-said-ai-s-most-profound-impact-will-be-in-life-sciences-ff53d3285e734bffPharma Surgeen2026-07-11T15:57:00.000ZNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?https://www.pharmaradar360.com/article/sopan-pharmaceutical-ipo-result-sopan-ipo-result-ipo-result-published-ipo-result-0bc4ac7d8bd2592fPharma Surgeen2026-07-11T15:44:34.000ZSopan Pharmaceutical Ipo Result | Sopan Ipo Result | Ipo Result Published | Ipo Result Zac Polanski (FX4vllUDsA)https://www.pharmaradar360.com/article/maharashtra-fda-bans-aciloc-150-and-300-orders-recall-over-medication-confusion-d41abd93de553e03Pharma Surgeen2026-07-11T15:06:12.000ZMaharashtra FDA Bans Aciloc 150+ And 300+, Orders Recall Over Medication Confusion Concernshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-concord-biotech-ltd-nse-concordbio-2d07f65229b43ea1Pharma Surgeen2026-07-11T14:22:49.000ZEnterprise value to revenue forward of Concord Biotech Ltd. – NSE:CONCORDBIOhttps://www.pharmaradar360.com/article/african-scientists-to-boost-biotech-research-capacity-c16356c60d4fda27Pharma Surgeen2026-07-11T14:22:18.000ZAfrican scientists to boost biotech research capacityhttps://www.pharmaradar360.com/article/argenx-a-biotech-powerhouse-poised-for-broad-expansion-58dc8f43049008f8Pharma Surgeen2026-07-11T14:21:49.000ZArgenx: A Biotech Powerhouse Poised for Broad Expansionhttps://www.pharmaradar360.com/article/moroccan-pharmaceutical-maker-galenica-opens-door-to-russian-and-eurasian-market-8093fa0de2ee87f5Pharma Surgeen2026-07-11T14:20:46.000ZMoroccan Pharmaceutical Maker Galenica Opens Door to Russian and Eurasian Markethttps://www.pharmaradar360.com/article/is-the-fda-poised-to-reshape-the-peptide-market-09dec58936fee636Pharma Surgeen2026-07-11T14:20:07.000ZIs the FDA Poised to Reshape the Peptide Markethttps://www.pharmaradar360.com/article/swedbank-ab-makes-new-11-45-million-investment-in-teva-pharmaceutical-industries-d11e7e26dd583c27Pharma Surgeen2026-07-11T14:18:38.000ZSwedbank AB Makes New $11.45 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/biotech-stock-performance-gap-widens-during-second-quarter-of-2026-bfb36ff8fe1ca4f6Pharma Surgeen2026-07-11T14:03:49.000ZBiotech Stock Performance Gap Widens During Second Quarter of 2026https://www.pharmaradar360.com/article/maharashtra-fda-bars-sale-of-two-cadila-drugs-over-branding-concerns-5e9eb485b445d35fPharma Surgeen2026-07-11T14:03:00.000ZMaharashtra FDA bars sale of two Cadila drugs over branding concernshttps://www.pharmaradar360.com/article/okyo-pharma-advances-toward-phase-3-fda-trial-icymi-ee230e5505298f01Pharma Surgeen2026-07-11T14:00:19.000ZOKYO Pharma advances toward Phase 3 FDA trial - ICYMIhttps://www.pharmaradar360.com/article/maharashtra-fda-bars-sale-of-some-cadila-pharma-drugs-over-brand-confusion-c623e56b1a35f7f5Pharma Surgeen2026-07-11T13:55:37.000ZMaharashtra FDA bars sale of some Cadila Pharma drugs over brand confusionhttps://www.pharmaradar360.com/article/octozi-raises-3-million-seed-to-bring-agentic-ai-into-clinical-trial-data-operat-73538cafeda1dd6dPharma Surgeen2026-07-11T13:53:26.000ZOctozi Raises $3 Million Seed To Bring Agentic AI Into Clinical Trial Data Operationshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-wakamoto-pharmaceutical-co-ltd-tse-4512-44a037b715b4f4f1Pharma Surgeen2026-07-11T13:29:06.000ZPrice to sales forward of Wakamoto Pharmaceutical Co., Ltd. – TSE:4512https://www.pharmaradar360.com/article/what-do-the-povorcitinib-trial-results-mean-for-incyte-11df5fd0182e2d65Pharma Surgeen2026-07-11T13:19:01.000ZWhat Do the Povorcitinib Trial Results Mean for Incytehttps://www.pharmaradar360.com/article/equitable-trust-co-invests-2-59-million-in-teva-pharmaceutical-industries-ltd-te-83059a174f577b45Pharma Surgeen2026-07-11T13:02:27.000ZEquitable Trust Co. Invests $2.59 Million in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/what-do-the-latest-summit-trial-data-mean-for-bezuclastinib-375c7e48798aa32cPharma Surgeen2026-07-11T12:48:23.000ZWhat Do the Latest SUMMIT Trial Data Mean for Bezuclastinibhttps://www.pharmaradar360.com/article/gsk-scores-key-win-as-hansoh-s-lung-cancer-drug-meets-phase-iii-survival-goal-1f6a744a7582aeadPharma Surgeen2026-07-11T12:45:47.000ZGSK Scores Key Win as Hansoh's Lung Cancer Drug Meets Phase III Survival Goalhttps://www.pharmaradar360.com/article/5-glp-1-trends-to-expect-in-2026-expanded-uses-oral-options-and-more-a72fa01a22fd1a9bPharma Surgeen2026-07-11T12:18:00.000Z5 GLP-1 Trends to Expect in 2026: Expanded Uses, Oral Options, and Morehttps://www.pharmaradar360.com/article/strong-biotech-screener-projectsyndicate-indicator-by-projectsyndicate-2f464ede61cc33acPharma Surgeen2026-07-11T12:02:34.000ZStrong Biotech Screener | ProjectSyndicate — Indicator by ProjectSyndicatehttps://www.pharmaradar360.com/article/a-tiny-glp-1-implant-is-the-latest-bet-to-help-patients-maintain-their-weight-lo-5d67450656fa0ff1Pharma Surgeen2026-07-11T12:00:01.000ZA tiny GLP-1 implant is the latest bet to help patients maintain their weight losshttps://www.pharmaradar360.com/article/why-is-sanofi-s-tolebrutinib-facing-a-regulatory-split-941a9c08b59ee378Pharma Surgeen2026-07-11T11:52:23.000ZWhy is Sanofi's Tolebrutinib Facing a Regulatory Splithttps://www.pharmaradar360.com/article/novartis-vs-teva-which-pharmaceutical-stock-is-a-better-buy-in-2026-7a940c7104080a45Pharma Surgeen2026-07-11T11:33:35.000ZNovartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?https://www.pharmaradar360.com/article/kos-pharmaceuticals-in-the-spotlight-as-biotech-gateway-for-greece-8e715c587a22a3efPharma Surgeen2026-07-11T11:22:50.000ZKos Pharmaceuticals in the Spotlight as Biotech Gateway for Greecehttps://www.pharmaradar360.com/article/biotech-stocks-face-big-15b-hit-as-vertex-ionis-skew-flat-weekly-tape-469d4272af0cf581Pharma Surgeen2026-07-11T11:07:10.000ZBiotech Stocks Face Big $15B Hit as Vertex, Ionis Skew Flat Weekly Tapehttps://www.pharmaradar360.com/article/is-edgewise-therapeutics-ewtx-on-the-cusp-of-a-breakthrough-year-62f693b42cd85a30Pharma Surgeen2026-07-11T10:57:49.000ZIs Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Yearhttps://www.pharmaradar360.com/article/gel-strength-tester-market-forecast-points-higher-toward-2035-driven-by-pharmace-f5708f0f632fa712Pharma Surgeen2026-07-11T10:36:12.000ZGel Strength Tester Market Forecast Points Higher Toward 2035 Driven by Pharmaceutical Quality Mandateshttps://www.pharmaradar360.com/article/futura-medical-partners-with-mpg-for-us-sales-a-279b7f1b9196da5ePharma Surgeen2026-07-11T10:19:28.000ZFutura Medical partners with MPG for US sales a...https://www.pharmaradar360.com/article/fdaaa-updated-to-include-social-media-in-medication-advertising-45db9008ccdfb50dPharma Surgeen2026-07-11T10:01:00.000ZFDAAA updated to include social media in medication advertisinghttps://www.pharmaradar360.com/article/futura-medical-us-eroxon-deal-and-wsd4000-breakthrough-icymi-d10cc49d239452f3Pharma Surgeen2026-07-11T09:45:21.000ZFutura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMIhttps://www.pharmaradar360.com/article/futura-medical-us-eroxon-deal-and-wsd4000-breakthrough-icymi-707778baa55bfa8cPharma Surgeen2026-07-11T09:38:00.000ZFutura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMIhttps://www.pharmaradar360.com/article/tampa-general-hospital-sues-major-pharmaceutical-company-over-drug-pricing-988749d6df0d399fPharma Surgeen2026-07-11T09:35:46.000ZTampa General Hospital sues major pharmaceutical company over drug pricinghttps://www.pharmaradar360.com/article/why-illinois-patients-need-the-340b-drug-program-opinion-194a36c243085920Pharma Surgeen2026-07-11T08:30:00.000ZWhy Illinois patients need the 340B drug program | Opinionhttps://www.pharmaradar360.com/article/chinese-biotech-mindrank-secures-52m-to-advance-ai-designed-oral-glp-1ra-9a4e968fa90d0bb4Pharma Surgeen2026-07-11T08:01:41.000ZChinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RAhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-emmessar-biotech-nutrition-ltd-bse-emmessa-91757bb9bad2fb34Pharma Surgeen2026-07-11T07:05:54.000ZEnterprise value to EBIT forward of Emmessar Biotech & Nutrition Ltd. – BSE:EMMESSAhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-hunan-warrant-pharmaceutical-co-ltd-class-a-sse-688799-dbbb6c007332616cPharma Surgeen2026-07-11T07:04:34.000ZPrice to sales forward of Hunan Warrant Pharmaceutical Co., Ltd. Class A – SSE:688799https://www.pharmaradar360.com/article/is-viking-therapeutics-poised-to-disrupt-the-weight-loss-market-afb5e819ae6f724ePharma Surgeen2026-07-11T07:00:26.000ZIs Viking Therapeutics Poised to Disrupt the Weight-Loss Markethttps://www.pharmaradar360.com/article/fda-s-single-trial-default-what-it-actually-means-for-your-protocol-strategy-043fdd9a6bc99a33Pharma Surgeen2026-07-11T06:43:52.000ZFDA’s Single-Trial Default: What It Actually Means for Your Protocol Strategyhttps://www.pharmaradar360.com/article/u-s-biotechs-are-keeping-more-secrets-to-beat-copycats-in-china-dc8d77f710a01a01Pharma Surgeen2026-07-11T05:31:44.000ZU.S. Biotechs Are Keeping More Secrets to Beat Copycats in Chinahttps://www.pharmaradar360.com/article/2-fast-growing-pharmaceutical-stocks-to-buy-now-66c3363883b61229Pharma Surgeen2026-07-11T05:03:44.000Z2 Fast-Growing Pharmaceutical Stocks to Buy Nowhttps://www.pharmaradar360.com/article/sleep-apnea-pill-maker-apnimed-files-for-us-ipo-as-biotech-market-revives-327891e0999d2e6cPharma Surgeen2026-07-11T04:29:15.000ZSleep apnea pill maker Apnimed files for US IPO as biotech market reviveshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-rohto-pharmaceutical-co-ltd-tse-4527-ceaf39dc01c6ced8Pharma Surgeen2026-07-11T02:57:30.000ZPrice to earnings forward of Rohto Pharmaceutical Co., Ltd. – TSE:4527https://www.pharmaradar360.com/article/fda-suspends-kondhwa-cafe-s-licence-for-allegedly-serving-expired-food-products-3b14d221aa52676dPharma Surgeen2026-07-11T02:55:33.000ZFDA suspends Kondhwa cafe’s licence for allegedly serving expired food products | Hindustan Timeshttps://www.pharmaradar360.com/article/phanes-therapeutics-announces-updated-phase-2-clinical-trial-results-of-spevatam-c671cc12b317de93Pharma Surgeen2026-07-11T02:43:49.000ZPhanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meetinghttps://www.pharmaradar360.com/article/biopharma-divides-over-china-response-73c2b967a824c532Pharma Surgeen2026-07-11T02:43:13.000ZBiopharma divides over China responsehttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-kwang-dong-pharmaceutical-co-ltd-krx-009290-f0554c772cd5e8b1Pharma Surgeen2026-07-11T01:30:30.000ZPrice to earnings forward of Kwang Dong Pharmaceutical Co., Ltd. – KRX:009290https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-sells-smartdose-rights-is-the-stock-fully-price-34650f31521a8a84Pharma Surgeen2026-07-11T01:02:38.000ZWest Pharmaceutical Services (WST) Sells SmartDose Rights, Is The Stock Fully Priced?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-rtw-biotech-opportunities-ltd-usd-swb-0bm-6dd4bfd95d5de526Pharma Surgeen2026-07-11T00:49:17.000ZEnterprise value to EBITDA forward of RTW Biotech Opportunities Ltd USD – SWB:0BMhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-ed2e720306f46479Pharma Surgeen2026-07-11T00:21:44.000ZPrice to earnings forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-8e52c3b21214ab52Pharma Surgeen2026-07-11T00:09:53.000ZEnterprise value to EBIT forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/price-to-sales-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-514f64d087bad06aPharma Surgeen2026-07-11T00:06:05.000ZPrice to sales forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/a-longitudinal-disease-progression-model-characterizing-endoscopic-response-and-13ce7d8aaa7e1564Pharma Surgeen2026-07-11T00:00:00.000ZA Longitudinal Disease Progression Model Characterizing Endoscopic Response and Remission in Crohn's Disease.